EUVIMEDOpdag EUVIMED
Open access

Pediatric spontaneous‐reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system

Yue Zhang iD, Yile Liu iD, Lingli Chen, Yating Chen iD, Xiangrong Zheng

Pediatric Allergy and Immunology · 2026

DOI: 10.1111/pai.70495 ↗

At a glance

Journal article in Pediatric Allergy and Immunology, 2026. Written by Yue Zhang and 4 co-authors. Institution: Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China. Major MEDLINE topics: Asthma, Adverse Drug Reaction Reporting Systems, Anti-Asthmatic Agents, Biological Products. 32 references. The full text is freely available in PubMed Central. Funded by: the Natural Science Foundation of Hunan Province, China, the Degree and Postgraduate Education Reform Project of Central South University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Pediatric post‐marketing evidence for biologics used for asthma remains limited and uneven across agents. We characterized pediatric spontaneous‐reporting patterns for biologics approved or used for asthma in the FDA Adverse Event Reporting System.

Methods

We analyzed pediatric reports involving omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab from 2015 through 2025. Reports were summarized by age, sex, reporting year, outcomes, and preferred terms. Serious‐outcome and indication‐linked classifications were performed. Disproportionality was assessed using reporting odds ratios, proportional reporting ratios, chi‐square statistics, and information components. Pediatric signals were compared with adult findings and interpreted according to method agreement, report volume, and sparse‐data restrictions.

Results

We identified 5155 pediatric reports. Dupilumab accounted for 3787 reports (73.5%) and omalizumab for 1152 (22.3%). Serious outcomes were reported in 1273 reports (24.7%), with substantial variation across biologics. Dupilumab showed prominent injection‐site, dermatologic, and ocular reporting, whereas omalizumab showed respiratory, asthma‐related, hypersensitivity‐related, and vital‐sign reporting. Of 43 pediatric signals supported by at least two disproportionality criteria, 31 were also identified in adults. After restricting to terms with at least five reports, 33 signals remained for the main analysis. Narrow anaphylaxis‐related domains occurred in 17 dupilumab, 113 omalizumab, 3 mepolizumab, 3 benralizumab, and no tezepelumab reports. Among dupilumab reports, 83.4% were classified as asthma‐related and 15.2% as mixed indications.

Conclusions

Pediatric FAERS reports showed biologic‐specific reporting patterns. These patterns may reflect potential drug‐related events, underlying disease activity, treatment failure, indication mix, monitoring, and reporting practices. The findings are hypothesis‐generating and do not establish incidence, causality, or asthma‐specific safety profiles. image

Subjects

MeSH terms (MEDLINE)

AsthmaAdverse Drug Reaction Reporting SystemsAnti-Asthmatic AgentsBiological ProductsHumansChildUnited StatesUnited States Food and Drug AdministrationFemaleAdolescentMaleChild, PreschoolInfantAntibodies, Monoclonal, HumanizedOmalizumab

Author keywords

FAERSadverse event reportingbiologicsdisproportionality analysisdupilumabomalizumabpediatric asthmapharmacovigilance

Substances

Anti-Asthmatic AgentsBiological ProductsAntibodies, Monoclonal, HumanizedOmalizumabdupilumab

Authors and institutions

  • Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • The Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID profiles: Yue Zhang, Yile Liu, Yating Chen

Funding

  • the Natural Science Foundation of Hunan Province, China
  • the Degree and Postgraduate Education Reform Project of Central South University

Cite

APA

Zhang, Y., Liu, Y., Chen, L., Chen, Y., & Zheng, X. (2026). Pediatric spontaneous‐reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70495

Vancouver

Zhang Y, Liu Y, Chen L, Chen Y, Zheng X. Pediatric spontaneous‐reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70495

BibTeX
@article{Zhang2026,
  author = {Zhang, Yue and Liu, Yile and Chen, Lingli and Chen, Yating and Zheng, Xiangrong},
  title = {Pediatric spontaneous‐reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  doi = {10.1111/pai.70495}
}
Start for free →